New Jersey Assembly Bill AR171

New Jersey 2022-2023 Regular Session

• Introduced: 1/10/23
• Refer: 1/10/23

Caption

Urges federal Food and Drug Administration to ease restrictions on gay and bisexual men donating blood.

Impact

The resolution highlights advancements in HIV testing and treatment since the establishment of past restrictions based on outdated assessments of risk. It advocates for a shift from categorical bans to individualized risk assessments, which many health professionals support as a more scientifically valid and equitable approach. By promoting this transition, the resolution aims to increase the number of eligible donors, thereby potentially alleviating blood supply shortages and better meeting the health needs of the population.

Summary

Assembly Resolution AR171 calls on the federal Food and Drug Administration (FDA) to ease restrictions on blood donations from gay and bisexual men, specifically urging the removal of the three-month abstinence requirement that is currently in place. This resolution underscores the importance of blood donation in healthcare, noting that blood is crucial for various medical treatments. AR171 is introduced in the context of significant blood shortages, exacerbated by the COVID-19 pandemic, which have led to calls for a more inclusive donor base.

Contention

AR171 addresses the contention surrounding the existing policies that are perceived as discriminatory against gay and bisexual men. Advocacy groups argue that these bans are outdated and not reflective of current scientific understanding. They stress that risk assessments should consider individual behaviors rather than broad categorizations, thus eliminating stigma against the LGBTQ+ community. The resolution calls on the FDA to update its criteria, reflecting ongoing medical advancements and changing social attitudes towards blood donation and sexual orientation.